Agenus Inc Stock Price To Earning
| AGEN Stock | USD 3.42 0.07 2.01% |
Agenus Inc fundamentals help investors to digest information that contributes to Agenus' financial success or failures. It also enables traders to predict the movement of Agenus Stock. The fundamental analysis module provides a way to measure Agenus' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Agenus stock.
Agenus | Price To Earning |
Agenus Inc Company Price To Earning Analysis
Agenus' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Agenus Price To Earning | 10.52 X |
Most of Agenus' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Agenus Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Agenus Price To Earning Driver Correlations
Understanding the fundamental principles of building solid financial models for Agenus is extremely important. It helps to project a fair market value of Agenus Stock properly, considering its historical fundamentals such as Price To Earning. Since Agenus' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Agenus' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Agenus' interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Agenus Retained Earnings
Based on the latest financial disclosure, Agenus Inc has a Price To Earning of 10.52 times. This is 59.29% lower than that of the Biotechnology sector and 113.39% higher than that of the Health Care industry. The price to earning for all United States stocks is 63.37% higher than that of the company.
Did you try this?
Run Odds Of Bankruptcy Now
Odds Of BankruptcyGet analysis of equity chance of financial distress in the next 2 years |
| All Next | Launch Module |
Agenus ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Agenus' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Agenus' managers, analysts, and investors.Environmental | Governance | Social |
Agenus Fundamentals
| Return On Equity | -12.79 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (1.42) % | ||||
| Operating Margin | (1.33) % | ||||
| Current Valuation | 114.36 M | ||||
| Shares Outstanding | 23.61 M | ||||
| Shares Owned By Insiders | 1.24 % | ||||
| Shares Owned By Institutions | 37.14 % | ||||
| Number Of Shares Shorted | 2.62 M | ||||
| Price To Earning | 10.52 X | ||||
| Price To Book | 218.61 X | ||||
| Price To Sales | 0.51 X | ||||
| Revenue | 156.31 M | ||||
| Gross Profit | 82.61 M | ||||
| EBITDA | (145.92 M) | ||||
| Net Income | (245.76 M) | ||||
| Cash And Equivalents | 218.23 M | ||||
| Cash Per Share | 0.72 X | ||||
| Total Debt | 350.25 M | ||||
| Debt To Equity | 5.88 % | ||||
| Current Ratio | 1.45 X | ||||
| Book Value Per Share | (13.48) X | ||||
| Cash Flow From Operations | (224.2 M) | ||||
| Short Ratio | 5.51 X | ||||
| Earnings Per Share | (11.02) X | ||||
| Target Price | 8.0 | ||||
| Number Of Employees | 389 | ||||
| Beta | 1.39 | ||||
| Market Capitalization | 82.41 M | ||||
| Total Asset | 313.91 M | ||||
| Retained Earnings | (1.96 B) | ||||
| Working Capital | (143.48 M) | ||||
| Current Asset | 63.4 M | ||||
| Current Liabilities | 9.97 M | ||||
| Net Asset | 313.91 M |
About Agenus Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Agenus Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Agenus using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Agenus Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Agenus
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agenus position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agenus will appreciate offsetting losses from the drop in the long position's value.Moving against Agenus Stock
| 0.89 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.79 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.71 | VTRS | Viatris | PairCorr |
| 0.68 | GILD | Gilead Sciences | PairCorr |
| 0.64 | EWTX | Edgewise Therapeutics | PairCorr |
The ability to find closely correlated positions to Agenus could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agenus when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agenus - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agenus Inc to buy it.
The correlation of Agenus is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agenus moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agenus Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agenus can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Agenus Piotroski F Score and Agenus Altman Z Score analysis. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agenus. If investors know Agenus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agenus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.02) | Revenue Per Share 7.808 | Quarterly Revenue Growth 0.033 | Return On Assets (0.22) | Return On Equity (12.79) |
The market value of Agenus Inc is measured differently than its book value, which is the value of Agenus that is recorded on the company's balance sheet. Investors also form their own opinion of Agenus' value that differs from its market value or its book value, called intrinsic value, which is Agenus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agenus' market value can be influenced by many factors that don't directly affect Agenus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agenus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Agenus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agenus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.